Switching from Tracleer to Opsumit May Benefit Some PAH Patients
Switching from Tracleer (bosentan) to Opsumit (macitentan) improved physical abilities with fewer side effects in some adults with pulmonary arterial hypertension (PAH), a study showed. Replacing Tracleer with Opsumit may be a feasible treatment option in PAH patients who did not fully respond to Tracleer alone or…